Northern Cross LLC Has $591.17 Million Position in Teva Pharmaceutical Industries Limited (TEVA)

Northern Cross LLC increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,795,579 shares of the company’s stock after purchasing an additional 2,184,172 shares during the period. Teva Pharmaceutical Industries Limited accounts for 7.6% of Northern Cross LLC’s portfolio, making the stock its 6th biggest position. Northern Cross LLC owned approximately 1.75% of Teva Pharmaceutical Industries Limited worth $591,169,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Capital Research Global Investors boosted its holdings in Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after acquiring an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after acquiring an additional 6,685,844 shares in the last quarter. FMR LLC boosted its holdings in Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after acquiring an additional 6,115,853 shares in the last quarter. Capital World Investors boosted its holdings in Teva Pharmaceutical Industries Limited by 41.9% in the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after acquiring an additional 3,268,200 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Teva Pharmaceutical Industries Limited by 32.3% in the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock worth $378,688,000 after acquiring an additional 2,782,257 shares in the last quarter. 56.75% of the stock is currently owned by institutional investors.

Several equities research analysts have commented on the company. Royal Bank Of Canada dropped their target price on Teva Pharmaceutical Industries Limited from $21.00 to $15.00 and set an “underperform” rating on the stock in a report on Monday, September 18th. Wells Fargo & Company reissued a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, October 5th. Credit Suisse Group set a $39.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Thursday, August 3rd. Maxim Group reissued a “hold” rating and issued a $15.50 target price on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, September 14th. Finally, Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Thursday, June 22nd. Five research analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $27.63.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 3.17% during mid-day trading on Friday, reaching $14.67. The company’s stock had a trading volume of 15,362,449 shares. Teva Pharmaceutical Industries Limited has a 12-month low of $14.30 and a 12-month high of $44.49. The firm’s 50-day moving average price is $16.76 and its 200 day moving average price is $26.28. The firm’s market cap is $14.90 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the prior year, the firm earned $1.25 EPS. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, analysts expect that Teva Pharmaceutical Industries Limited will post $4.25 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were paid a $0.085 dividend. The ex-dividend date was Friday, August 25th. This represents a $0.34 annualized dividend and a dividend yield of 2.24%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.

ILLEGAL ACTIVITY WARNING: This report was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2957772/northern-cross-llc-has-591-17-million-position-in-teva-pharmaceutical-industries-limited-teva.html.

Teva Pharmaceutical Industries Limited Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.